The IPO provides Attovia with ~$289M in cash to fund its pipeline through key clinical milestones. Traders should watch for early trading volume and price stability on August 5, as well as any updates on ATTO-1310 clinical data or IND filings for ATTO-2306/ATTO-1091. The over-allotment option could add further dilution if exercised.
Price Chart
Executive Summary
Attovia Therapeutics priced its upsized IPO of 17M shares at $17.00/share, raising $289M in gross proceeds. The company is a clinical-stage biopharma with no approved products, so the IPO provides a substantial cash runway for its pipeline (ATTO-1310, ATTO-2306, ATTO-1091) but also represents significant dilution for existing holders. The stock begins trading on Nasdaq on August 5, 2026.
Key Financial Metrics
Key Facts
- IPO of 17,000,000 shares priced at $17.00/share
- Gross proceeds of $289.0 million before expenses
- Underwriters have a 30-day option to purchase up to an additional 2,550,000 shares
- Stock expected to begin trading on Nasdaq on August 5, 2026 under symbol ATTO
- Offering expected to close on August 6, 2026
- Lead programs: ATTO-1310 (anti-IL-31, clinical), ATTO-2306 (bispecific IL-31/IL-13, IND-enabling), ATTO-1091 (trispecific TL1A/IL-23p19/integrin α4β7, IND-enabling)
- Company is clinical-stage with no approved products
Financial Impact
$289.0 million gross proceeds from IPO; dilution of 17M shares (plus up to 2.55M additional from over-allotment)
Risk Factors
- Clinical-stage company with no approved products — pipeline risk is high
- Dilution from 17M new shares (plus potential 2.55M over-allotment)
- IPO pricing at $17.00 may not hold if market conditions shift or if early trading is weak
- Competition in IL-31, IL-13, TL1A/IL-23/integrin spaces from larger, better-funded players
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3338994 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Oct 8, 2026 18d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Sep 28, 2026 28d ago | Press Release | $18.16 | awaiting T+20 | — | $13.88 (−23.57%) |
Sep 2, 2026 7w ago | Press Release | $24.20 $17.14 | ▼ −29.17% | ▼ −28.06% | $13.88 (−42.64%) |
Aug 28, 2026 8w ago | 144 / CLUSTER | $21.40 $18.16 | ▼ −15.14% | ▼ −14.95% | $13.88 (−35.14%) |
Aug 13, 2026 10w ago | Insider Buy | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 13, 2026 10w ago | Insider Cluster | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.65 $22.86 | ▲ +22.57% | ▲ +23.63% | $13.88 (−25.58%) |
Aug 7, 2026 11w ago | Insider Cluster | $19.84 $23.66 | ▲ +19.25% | ▲ +20.17% | $13.88 (−30.04%) |
Aug 7, 2026 11w ago | Insider Cluster | $20.17 $25.55 | ▲ +26.67% | ▲ +27.07% | $13.88 (−31.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers